Internal Medicine, Hospices Civils De Lyon, Lyon, France
Internal Medicine, Hopital De La Croix-Rousse,Lyon, France.
Br J Ophthalmol. 2021 Jul;105(7):935-940. doi: 10.1136/bjophthalmol-2020-315862. Epub 2020 Jul 24.
To assess vision-related (VR-QOL) and health-related quality of life (HR-QOL) in a large series of patients with de novo uveitis at baseline and 6-month follow-up.
Non-inferiority, prospective, multicentre, cluster randomised controlled trial registered under the Unique Identifier: NCT01162070. VR-QOL and HR-QOL were assessed by the 25-item National Eye Institute Visual Function Questionnaire (VFQ-25) and the Medical Outcomes Study 36-item Short Form Survey (SF-36).
At inclusion, 466 patients completed the VFQ-25. The mean composite score was 80.0 (±16.7). In multivariate analysis, higher age, female sex and insidious onset were significantly associated with lower QOL. At 6 months, 138 patients completed the VFQ-25, with a significantly higher mean composite score of 82.6 (±16.7). SF-36 mental component was 42.9 (±11.3) and physical component was 47.2 (±8.5) at inclusion (n=425). HR-QOL improvement at 6 months was not clinically significant.
QOL seems relatively well preserved in this cohort; only VR-QOL improved significantly at 6 months, especially in patients with low initial visual acuity.
在一项新发病变性葡萄膜炎患者的大型系列研究中，评估基线和 6 个月随访时与视觉相关（VR-QOL）和健康相关的生活质量（HR-QOL）。
非劣效性、前瞻性、多中心、集群随机对照试验，注册号：NCT01162070。通过 25 项国家眼科研究所视觉功能问卷（VFQ-25）和医疗结局研究 36 项简短调查问卷（SF-36）评估 VR-QOL 和 HR-QOL。
纳入时，466 例患者完成了 VFQ-25。平均综合评分为 80.0（±16.7）。多因素分析显示，年龄较大、女性和隐匿性发病与较低的 QOL 显著相关。6 个月时，138 例患者完成了 VFQ-25，平均综合评分显著升高至 82.6（±16.7）。纳入时 SF-36 心理成分评分为 42.9（±11.3），生理成分评分为 47.2（±8.5）（n=425）。6 个月时 HR-QOL 改善无临床意义。
该队列的 QOL 似乎相对较好；仅 VR-QOL 在 6 个月时显著改善，尤其是在初始视力较低的患者中。
